or genome editing, such as modification, augmentation, or depletion. The requirement can be achieved through delivery of molecular cargo (DNA, RNA, or protein) into cells, including zinc finger nucleases (ZFNs), [2] transcription activatorlike effector nucleases (TALENs), [3] and CRISPR and associated nucleases such as Cas9. [4] Thus, improving cargo delivery is critical for development of powerful tools used in cell engineering. Molecular cargo can be delivered into cells using either viral or nonviral methods. [5] Compared to nonviral ones, viral methods are in general more efficient. However, they are immunogenic, expensive, and potentially unsafe for clinical use. [6] In addition, viral vehicles have limited delivery capacity. [7] Nonviral methods such as electrotransfer (or electroporation) are increasingly being used in cell engineering. [8] Nonviral delivery is more cost-effective, multiplexable, and applicable to a wide variety of cargo than viral delivery, but currently considered to be inefficient in clinical applications. The low efficiency is often caused by enzymatic degradation of cargo in lysosomes before reaching the target site. Strategies to avoid degradation include facilitating endosomal escape, blocking vesicular transport to lysosomes, and inactivating lysosomal enzymes. Here we propose a new strategy called Pretreatment for Redirection of Endocytic and Autophagic Traffic (pTREAT) that increases the half-life of molecular cargo in cells. The increase is achieved by priming cells with a family of sugar molecules that are disaccharides or oligosaccharides (such as sucrose, trehalose, and raffinose) and cannot be broken down or degraded in mammalian cells. Treatment of cells with the nondegradable sugars (NDSs) can enlarge lysosomes and induce the formation of large nonacidic vesicles called amphisome-like bodies (ALBs), which hinder vesicular trafficking to lysosomes and redirect transport to ALBs. Both changes are reversible and lead to reduction in cargo degradation. To demonstrate the capabilities of the pTREAT method, we applied it to improving the efficiency of electrotransfer of several types of cargo-plasmid DNA, mRNA, Sleeping Beauty transposon, and the CRISPR/Cas9 system-into various cell types including human primary T cells, without compromising cell viability. Cell engineering relies heavily on viral vectors for the delivery of molecular cargo into cells due to their superior efficiency compared to nonviral ones. However, viruses are immunogenic and expensive to manufacture, and have limited delivery capacity. Nonviral delivery approaches avoid these limitations but are currently inefficient for clinical applications. This work demonstrates that the efficiency of nonviral delivery of plasmid DNA, mRNA, Sleeping Beauty transposon, and ribonucleoprotein can be significantly enhanced through pretreatment of cells with the nondegradable sugars (NDS), such as sucrose, trehalose, and raffinose. The enhancement is mediated by the incorporation of the NDS into cell membranes, causing enlar...